Dear Majority Leader Schumer, Minority Leader McConnell, Speaker Pelosi, and Minority Leader McCarthy:

On behalf of a broad spectrum of patients, advocacy organizations, cancer centers and healthcare professionals, we are writing today to express our support for the Reducing Hereditary Cancer Act (H.R. 4110/S.B. 3656), legislation that would ensure Medicare beneficiary access to genetic testing for hereditary cancer risk, increased screening and risk reducing interventions, when medically necessary and appropriate.

Under existing Medicare guidelines, only a person with “signs, symptoms, complaints, or personal histories of disease” meets the criteria for coverage of medical services. Recognizing the value of cancer prevention and early detection, in recent years Congress has passed legislation allowing for coverage of certain cancer screenings (e.g., mammograms, colonoscopies and PSA tests) for the “average risk” population.

There has been tremendous progress in cancer prevention, detection, and treatment over the past quarter century. Research shows that inherited genetic mutations play a major role in approximately 10% of cancers, including breast, ovarian, endometrial, prostate, pancreatic and colorectal. Major cancer organizations, genetics, and medical professional societies including the National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) and others have established guidelines for the assessment and management of hereditary cancer risk.

The U.S. Preventive Services Task Force recognizes the significance of genetics in cancer risk. In 2013, the Task Force published recommendations for Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer. For those with an inherited mutation, the USPSTF notes that management consists of “a variety of interventions to lower future cancer risk. This includes intensive screening, risk-reducing medications, and risk-reducing mastectomy and salpingo-oophorectomy.”
Medicare covers genetic testing only for beneficiaries already diagnosed with cancer (regardless of family cancer history or a known genetic mutation in the family). Most private insurers cover genetic counseling and testing for appropriate individuals, including those without a cancer diagnosis, as well as people with a cancer diagnosis. It is crucial that Medicare beneficiaries have access to the same cancer screening and preventive measures as their counterparts with private insurance.

If someone without cancer learns they have an inherited mutation that increases cancer risk (e.g., BRCA1 or BRCA2) prior to Medicare eligibility—or pays out of pocket for genetic testing and finds that they carry an inherited mutation while on Medicare—the individual cannot access the recommended high-risk cancer screenings. Medicare is not permitted to cover these screenings, despite the fact that they are proven to detect cancer earlier, when it is less invasive, less costly, and more easily treated.

Similarly, Medicare is barred from covering potentially lifesaving, risk-reducing procedures, such as bilateral salpingo-oophorectomy (removal ovaries and fallopian tubes). This surgery is crucial for women at high risk of ovarian cancer because there is no reliable screening or early detection; more than 75% of affected women are diagnosed with advanced-stage disease (Stage III or IV). Up to 25% of ovarian cancers are attributable to an inherited genetic mutation. The median age for diagnosis of ovarian cancer in the U.S. is 63 years, meaning almost half of all persons with ovarian cancer are Medicare beneficiaries. Furthermore, those aged 65 or older with ovarian cancer have significantly worse cancer-related survival than younger patients.

Medicare’s inability to cover these potentially life-saving tests and interventions exacerbates health disparities. Access to screening and risk-reducing interventions enables early detection and reduces risk for individuals who carry an inherited mutation. We must prioritize screening, early detection, and prevention in Medicare but to do this requires Congressional action. The National Cancer Institute (NCI) predicts nearly 10,000 excess deaths in the U.S. from breast and colorectal cancer alone over the next 10 years because of pandemic-related delays in cancer screening and treatment. Enactment of the Reducing Hereditary Cancer Act of 2021 (H.R. 4110/S.B. 3656) will improve access to critical screening and preventive care, and may mitigate some of the predicted cancer-related deaths over the next decade and beyond.

We encourage your support of this lifesaving legislation that will ultimately save Medicare tens of millions of dollars and thank you for your time and consideration today. Please contact Lisa Schlager at FORCE or Alyssa Schatz at NCCN with any questions.

Sincerely,

Patient Advocacy Organizations
AliveAndKickn
Alliance for Aging Research
Alliance for Patient Access
American Cancer Society Cancer Action Network
Breast Cancer Action
Brem Foundation to Defeat Breast Cancer
Bright Pink
Cancer ABCs
CancerCare
Cancer Support Community
Colon Cancer Alliance for Research & Education for Lynch Syndrome
Colon Cancer Coalition
Community Oncology Alliance Patient Advocacy Network (CPAN)
DenseBreast-info, Inc.
Disability Rights Legal Center
Dr. Susan Love Foundation for Breast Cancer Research
Fairview Health Services
Fight Colorectal Cancer
Florida Breast Cancer Foundation
FORCE - Facing Our Risk of Cancer Empowered
Genetic Alliance
GI Cancers Alliance
HealthyWomen
Hereditary Colon Cancer Foundation
HIS Breast Cancer Awareness
ICAN, International Cancer Advocacy Network
ICARE
Hope For Stomach Cancer
The Jewish Federations of North America
Kamie K Preston Hereditary Cancer Foundation
Let’s Win! Pancreatic Cancer
Living Beyond Breast Cancer
Living LFS
Lynch Syndrome International
Male Breast Cancer Coalition
National Alliance Against Disparities in Patient Health
National Coalition for Cancer Survivorship
National Ovarian Cancer Coalition
National Patient Advocate Foundation
NothingPink
Ovarian Cancer Project
Ovarian Cancer Research Alliance
Pancreatic Cancer Action Network
Prevent Cancer Foundation
Prostate Cancer Foundation
Raymond Foundation, Inc.
Research Advocacy Network
SHARE Cancer Support
Sharsheret | The Jewish Breast & Ovarian Cancer Community
Stupid Cancer, Inc.
Susan G. Komen
Thelma D. Jones Breast Cancer Fund
Tigerlily Foundation
Triage Cancer
Us TOO International, Inc.
Young Survival Coalition
ZERO - The End of Prostate Cancer
Academia/Professional Societies/Medical Institutions
Abramson Cancer Center, Penn Medicine
Academy of Oncology Nurse and Patient Navigators (AONN)
Advocate Aurora Health
American College of Medical Genetics and Genomics
American College of Obstetricians and Gynecologists (ACOG)
American Urological Association
The American Society of Breast Surgeons
Association for Clinical Oncology
Association for Molecular Pathology
Association of American Cancer Institutes
Association of Community Cancer Centers (ACCC)
Basser Center for BRCA, Penn Medicine
Center for Genomic Interpretation
Community Oncology Alliance (COA)
Consortium for Science, Policy & Outcomes, Arizona State University
Fairview Health Services
Florida Association of Genetic Counselors
Fox Chase Cancer Center
Georgetown Lombardi Comprehensive Cancer Center
Huntsman Cancer Institute at the University of Utah
IL Society of Genetic Professionals
Intermountain Healthcare
International Society of Nurses in Genetics
JScreen
The Lynch Syndrome Screening Network
MHealth Fairview
Michigan Cancer Genetics Alliance
Moffitt Cancer Center
National Association for Nurse Practitioners in Women's Health
National Cancer Registrars Association
National Comprehensive Cancer Network (NCCN)
National Society of Genetic Counselors
Northwestern University Feinberg School of Medicine
Oncology Nursing Society
Palo Alto Medical Foundation
Society of Gynecologic Oncology
Swedish Cancer Institute
UC Santa Cruz Genomics Institute
University of Miami
University of Rochester Medical Center
US Oncology Network
William C. Bernstein Familial Cancer Registry, University of Minnesota

1 American Society of Clinical Oncology, Genetic Testing Coverage & Reimbursement
2 National Cancer Institute, The Genetics of Cancer, Accessed March 22, 2021
3 JAMA | US Preventive Services Task Force | RECOMMENDATION STATEMENT, Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer, August 20, 2019
4 Am Fam Physician. 2016 Jun 1;93(11):937-944
5 American Cancer Society, Ovarian Cancer Risk Factors, Accessed March 19, 2021